Benzamide derivatives as blockers of Kv1.3 ion channel

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 6, 2003, Pages 1161-1164

  Miao, Shouwu ^a   Bao, Jianming ^a   Garcia, Maria L ^a   Goulet, Joung L ^a   Hong, Xingfang J ^a   Kaczorowski, Gregory J ^a   Kayser, Frank ^a   Koo, Gloria C ^a   Kotliar, Andrew ^a   Schmalhofer, William A ^a   Shah, Kashmira ^a   Sinclair, Peter J ^a   Slaughter, Robert S ^a   Springer, Marty S ^a   Staruch, Mary Jo ^a   Tsou, Nancy N ^a   Wong, Frederick ^a   Parsons, William H ^a   Rupprecht, Kathleen M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; ASSAY; BRAIN; CIS TRANS ISOMERISM; CONTROLLED STUDY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HUMAN; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

EID: 0037463761     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00014-3     Document Type: Article

References (16)

1. Kaczorowski G.J., Koo G.C. Perspect. Drug Discov. Des. 2:1994;233.
2. Lewis R.S., Cahalan M.D. Annu. Rev. Immunol. 13:1995;623.
3. Cahalan M.D., Chandy K.G. Curr. Opin. Biotechnol. 8:1997;749.
4. Leonard R.J., Garcia M.L., Slaughter R.S., Reuben J.P. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10094.
5. Lin C.S., Boltz R.C., Blake J.T., Nguyen M., Talento A., Fischer P.A., Springer M.S., Sigal N.H., Slaughter R.S., Garcia M.L., Kaczorowski G.J., Koo G.C. J. Exp. Med. 177:1993;637.
6. Hill R.J., Grant A.M., Volberg W., Faltynek C., Miller D., Pagani K., Baizman E., Wang S., Guiles J.W., Krafte D.S. Mol. Pharm. 48:1995;98.
7. Nguyen A., Kath J.C., Hanson D.C., Biggers M.S., Canniff P.C., Donovan C.B., Mather R.J., Rauer H., Aiyar J., Lepple-Wienhues A., Gutman G.A., Grissmer S., Cahalan M.D., Candy K.G. Mol. Pharm. 50:1996;1672.
8. Burgess L.E., Koch K., Cooper K., Biggers M.S., Ramchandani M., Smitrovich J.H., Gilbert E.J., Bruns M.J., Mather R.J., Donovan C.B., Hanson D.C. Bioorg. Med. Chem. Lett. 7:1997;1047.
9. Felix J.P., Bugianesi R.M., Schmalhofer Borris, Robert. B., Goetz M.A., Hensens O.D., Bao J., Kayser F., Parsons W.H., Rupprecht K., Garcia M.L., Kaczorowski G.J., Slaughter R.S. Biochemistry. 38:1999;4922.
10. Schmalhofer W.A., Bao J., McManus O.B., Green B., Matyskiela M., Wunderler D., Bugianesi R.M., Felix J.P., Hanner M., Linde-Arias A., Ponte C.G., Velasco L., Koo G., Staruch M.J., Miao S., Parsons W., Rupprecht K., Slaughter R.S., Kaczorowski G.J., Garcia M.L. Biochemistry. 41:2002;7781.
11. Koo G.C., Blake J.T., Shah K., Staruch M.J., Dumont F., Wunderler D., Sanchez M., McManus O.B., Fischer P., Boltz R.C., Goetz M.A., Baker R., Bao J., Kayser F., Rupprecht K.M., Parsons W.H., Tong X.C., Ita I.E., Pivnichny J., Vincent S., Cunningham P., Hora D. Jr., Kaczorowski G.J., Springer M.S. Cell. Immunol. 197:1999;99.
12. Lew A., Chamberlin A.R. Bioorg. Med. Chem. Lett. 23:1999;3267.
13. Ketone 9 is commercially available from Acros. When ketone 9 was directly reduced to 11 by LAH in THF at reflux, a ratio of 11 to 1 was obtained.
14. Compounds 18, 20-21, 25-26, 28-29, 30-32, 34-35, 39-40, 42-43, and 46 have been previously disclosed in ref 10.
15. Vianna-Jorge R., Oliveira C.F., Garcia M.L., Kaczorowski G.J., Suarez-Kurtz G. Br. J. Pharmacol. 131:2000;772.
16. Liu Y., Jurman M.E., Yellen G. Neuron. 16:1996;859.